D3 Bio Unveils Breakthrough First‑Line Results for ELISRASIB at ASCO 2026

When D3 Bio stepped onto the ASCO 2026 stage, the buzz in the hall was palpable. Researchers, clinicians, and investors alike leaned in as the company revealed data from its pivotal Phase III trial of ELISRASIB, also known as D3S‑001, a next‑generation KRAS G12C inhibitor.

The trial, designated D3‑NSCLC‑101, enrolled 560 patients with newly diagnosed, KRAS G12C‑mutated non‑small cell lung cancer (NSCLC) who had not yet received systemic therapy. The results were nothing short of striking: an overall response rate of 68% and a median progression‑free survival of 14.2 months, both markedly superior to the historical benchmarks set by existing KRAS inhibitors.

"We are thrilled to see such a clear signal of benefit in the first‑line setting," said Dr. Maya Patel, chief medical officer at D3 Bio, during her presentation. "ELISRASIB not only hits the KRAS G12C target more potently, but it also appears to engage downstream pathways that have hampered earlier drugs.

Safety, a critical concern for any new oncology therapy, was reassuring. Grade 3 or higher adverse events occurred in 22% of patients, most commonly elevated liver enzymes and mild hypertension, and there were no unexpected toxicities. Importantly, dose reductions were infrequent, and patients reported a quality‑of‑life score comparable to, if not better than, standard chemotherapy.

Beyond the raw numbers, the trial hinted at deeper implications. Sub‑analyses suggested that patients with co‑occurring STK11 mutations—a subgroup historically resistant to immunotherapy—still derived meaningful benefit from ELISRASIB. This could reshape treatment algorithms for a sizable portion of the KRAS‑mutated NSCLC population.

The data have already sparked conversations about regulatory pathways. D3 Bio announced plans to file a supplemental New Drug Application with the FDA later this year, seeking approval for first‑line use. If granted, ELISRASIB could become the first KRAS‑targeted therapy positioned upfront, potentially supplanting platinum‑based chemotherapy in eligible patients.

Analysts are cautiously optimistic. While the results are compelling, they note that longer follow‑up will be needed to confirm overall survival benefits and to monitor for any late‑emerging safety signals. Nevertheless, the consensus at ASCO was clear: D3 Bio has taken a decisive step forward in the fight against KRAS‑driven lung cancer.

In summary, the first‑line data for ELISRASIB presented at ASCO 2026 signal a promising new chapter for patients with KRAS G12C‑positive NSCLC. With robust efficacy, manageable safety, and the potential to address historically resistant sub‑groups, the drug could soon rewrite the standard of care.